Figure 1
Kaplan–Meier analysis of persistence to rivaroxaban treatment for all patients (A) and for all patients who were observed for at least 12 months (B), according to VKA pre-treatment.

Kaplan–Meier analysis of persistence to rivaroxaban treatment for all patients (A) and for all patients who were observed for at least 12 months (B), according to VKA pre-treatment.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close